Quick Answer
Iterum Therapeutics plc reported Net Income of -$24.77 million for fiscal year 2024.
Iterum Therapeutics plc Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$24.77M | +35.4% |
| 2023 | -$38.37M | +13.6% |
| 2022 | -$44.43M | +51.5% |
| 2021 | -$91.56M | -76.1% |
| 2020 | -$52.01M | +49.6% |
| 2019 | -$103.13M | -33.8% |
| 2018 | -$77.06M | -162.0% |
| 2017 | -$29.41M | -118.4% |
| 2016 | -$13.46M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.98M | -47.3% | -37.9% |
| June 30, 2025 | -$6.51M | -30.3% | -33.1% |
| March 31, 2025 | -$4.89M | +31.1% | +19.7% |
| September 30, 2024 | -$6.09M | -57.2% | -22.0% |
| June 30, 2024 | -$5.00M | +59.2% | +29.6% |
| March 31, 2024 | -$7.10M | +28.2% | -83.2% |
| September 30, 2023 | -$3.88M | +86.7% | +68.3% |
| June 30, 2023 | -$12.24M | -81.8% | -23.8% |
- Iterum Therapeutics plc showed an increase of +35.4% in Net Income compared to the prior fiscal year.
- Over the 2016–2024 period, Iterum Therapeutics plc’s net income has declined by 84.0% (from -$13.46 million to -$24.77 million).
- The most recent figure is from Iterum Therapeutics plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: